Tenshi Pharmaceuticals Private Limited

About Tenshi Pharmaceuticals Private Limited bond with ISIN: INE435X07027

In the competitive landscape of fixed income securities, detailed and comprehensive information is vital for both investors and market analysts. This bond, identified by the unique ISIN INE435X07027, represents a significant financial instrument. Issued by TENSHI PHARMACEUTICALS PRIVATE LIMITED, it comes with the following description: "SECURED UNRATED UNLISTED REDEEMABLE NON CONVERTIBLE DEBENTURES DATE OF MATURITY 06/04/2027". Although the bond is currently marked as active, its structure and historical context provide valuable insights into the world of debentures and non-convertible securities. The issuer, TENSHI PHARMACEUTICALS PRIVATE LIMITED, classified as Non PSU, plays an essential role in the market despite some details such as sector, industry, and issuer nature not being explicitly provided. Key identifiers like the Corporate Identification Number (CIN) U74999KA2016PTC094652 further bolster its credibility. With a coupon rate of N/A, this instrument has been meticulously managed with the assistance of Integrated Enterprises (India) Ltd., Bangalore and under the oversight of Catalyst Trusteeship Limited (Formerly GDA Trusteeship Limited), ensuring a strong operational framework. Examining the technical specifications, the bond’s face value is 1000000 with an issue size of 150. It was allotted on 10/6/2023 and is scheduled for redemption on 4/6/2027. Categorized under "PLAIN VANILLA DEBENTURES" and defined as Secured, the instrument is structured to meet specific investment objectives. Although options such as call or put are not applicable in this instance, the core attributes remain detailed and robust. A critical element in evaluating any fixed income instrument is its credit rating. No credit rating information is available for this bond. This insight helps potential investors understand that while the ratings spectrum is broad, a lower rating can indicate higher risk, prompting careful consideration before investing. The security measures add another layer of assurance. The asset cover is described as follows: first ranking exclusive charge by way of a pledge over 6750000 shares of Strides Pharma Science Limited and 821,918 shares of Solara Active Pharma Science Limited including any additional pledge over shares of Strides and/or Solara, in terms of the Debenture Trust Deed – a feature that, while requiring further inquiry for complete details, underscores the issuer’s commitment to providing some level of investor protection. Furthermore, the bond is supported by several documents. There are no additional documents available for this bond. These documents serve as a reference for additional details and provide transparency to interested parties. Additionally, there are similar bonds in the market such as the bond with ISIN INE435X07035 having a coupon rate of 4% and the bond with ISIN INE435X07043 having a coupon rate of 4% and the bond with ISIN INE435X08025 having a coupon rate of 4% and the bond with ISIN INE435X08017 having a coupon rate of 4%. Such comparable instruments offer a broader perspective on market positioning and allow investors to perform benchmark analysis. This detailed description is crafted to meet rigorous content standards and to offer exhaustive insights into every facet of the bond’s structure. Investors, analysts, and researchers alike can derive substantial value from this narrative, which underscores both the instrument’s inherent characteristics and its broader market positioning. Such elaborate coverage enhances investor confidence by providing a rich, comprehensive content base. Every element from issuance details to security measures and comparative insights is meticulously presented to facilitate an informed and robust market understanding.